167 related articles for article (PubMed ID: 21562972)
41. Novel strategies for the development of a vaccine for Parietaria allergy.
Bonura A; Colombo P
Int J Immunopathol Pharmacol; 2011; 24(2):297-304. PubMed ID: 21658304
[TBL] [Abstract][Full Text] [Related]
42. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber.
Meyer W; Narkus A; Salapatek AM; Häfner D
Allergy; 2013 Jun; 68(6):724-31. PubMed ID: 23621350
[TBL] [Abstract][Full Text] [Related]
43. Oral Immunotherapy Using Probiotic Ice Cream Containing Recombinant Food-Grade
Vasiee A; Falah F; Sankian M; Tabatabaei-Yazdi F; Mortazavi SA
J Immunol Res; 2020; 2020():2635230. PubMed ID: 33029537
[TBL] [Abstract][Full Text] [Related]
44. Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy.
Zielen S; Gabrielpillai J; Herrmann E; Schulze J; Schubert R; Rosewich M
Immunotherapy; 2018 Jun; 10(7):529-536. PubMed ID: 29562801
[TBL] [Abstract][Full Text] [Related]
45. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
46. Design and evaluation of a hypoallergenic peptide-based vaccine for Salsola kali allergy.
Tabesh S; Fanuel S; Fazlollahi MR; Yekaninejad MS; Kardar GA; Razavi SA
Int Immunopharmacol; 2019 Jan; 66():62-68. PubMed ID: 30445308
[TBL] [Abstract][Full Text] [Related]
47. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
[TBL] [Abstract][Full Text] [Related]
48. Intradermal grass pollen immunotherapy increases T
Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
[TBL] [Abstract][Full Text] [Related]
49. Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy.
Mikus M; Zandian A; Sjöberg R; Hamsten C; Forsström B; Andersson M; Greiff L; Uhlén M; Levin M; Nilsson P; van Hage M; Ohlin M
J Allergy Clin Immunol; 2021 Mar; 147(3):1077-1086. PubMed ID: 32791163
[TBL] [Abstract][Full Text] [Related]
50. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
[TBL] [Abstract][Full Text] [Related]
51. Association of allergic patients' phenotypes with IgE reactivity to recombinant pollen marker allergens.
Twardosz-Kropfmüller A; Singh MB; Niederberger V; Horak F; Kraft D; Spitzauer S; Valenta R; Swoboda I
Allergy; 2010 Mar; 65(3):296-303. PubMed ID: 19839972
[TBL] [Abstract][Full Text] [Related]
52. Humoral immune responses to recombinant tree pollen allergens (Bet v I and Bet v II) in mice: construction of a live oral allergy vaccine.
Vrtala S; Grote M; Ferreira F; Susani M; Stocker B; Kraft D; Valenta R
Int Arch Allergy Immunol; 1995; 107(1-3):290-4. PubMed ID: 7613152
[TBL] [Abstract][Full Text] [Related]
53. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.
Purohit A; Niederberger V; Kronqvist M; Horak F; Grönneberg R; Suck R; Weber B; Fiebig H; van Hage M; Pauli G; Valenta R; Cromwell O
Clin Exp Allergy; 2008 Sep; 38(9):1514-25. PubMed ID: 18564326
[TBL] [Abstract][Full Text] [Related]
54.
Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
Front Immunol; 2020; 11():2118. PubMed ID: 33013894
[TBL] [Abstract][Full Text] [Related]
55. IgE profiles of Bermuda grass pollen sensitised patients evaluated by Phleum pratense allergens Phl P 1, 2, 4, 5, 6 , 7, 11, 12.
Rossi RE; Monasterolo G; Prina P; Coco G; Operti D; Rossi L
Allergol Int; 2008 Jun; 57(2):157-64. PubMed ID: 18349590
[TBL] [Abstract][Full Text] [Related]
56. Olive pollen recombinant allergens: value in diagnosis and immunotherapy.
Rodríguez R; Villalba M; Batanero E; Palomares O; Quiralte J; Salamanca G; Sirvent S; Castro L; Prado N
J Investig Allergol Clin Immunol; 2007; 17 Suppl 1():4-10. PubMed ID: 18050565
[TBL] [Abstract][Full Text] [Related]
57. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro).
McCormack PL; Wagstaff AJ
Drugs; 2006; 66(7):931-8. PubMed ID: 16740007
[TBL] [Abstract][Full Text] [Related]
58. Allergen Immunotherapy for a Teenager with Seasonal Allergic Rhinitis Due to Grass Pollen: Subcutaneous or Sublingual Route?
Nelson HS; Durham SR
J Allergy Clin Immunol Pract; 2017; 5(1):52-57. PubMed ID: 28065341
[No Abstract] [Full Text] [Related]
59. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
60. Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial.
Shamji MH; Ceuppens J; Bachert C; Hellings P; Placier G; Thirion G; Bovy N; Durham SR; Duchateau J; Legon T; Pirotton S
J Allergy Clin Immunol; 2018 Jan; 141(1):448-451. PubMed ID: 29030102
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
